TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce that its preclinical data on optic nerve regeneration study was presented today at the Annual Meeting of the Association for Research in Vision and Ophthalmology (“ARVO) in Salt Lake City Utah, the world’s largest and most respected vision science conference.
The data, presented by Prof. Ygal Rotenstreich, lead investigator and Director of the Retinal Research Lab at Sheba Medical Center, showed that ExoPTEN restored retinal activity and improved optic nerve structure in a controlled rat model of optic nerve compression. The study, initially announced in July and December 2024, has since been expanded to include a larger group of animals.